{"id":"01545","slug":"nitrated-fatty-acids--01545","source":{"id":"01545","dataset":"techtransfer","title":"Nitrated-fatty Acids Modulation of Type II Diabetes","description_":"<p>University of Pittsburgh researchers have extracted a large quantity of total RNA from a robust laboratory strain of Hydractinia symbiolongicarpus, allowing for the development of powerful research tools. Hydractinia genomes contain many human disease genes not found in other species, and there is a growing need to better understand these genomes for research purposes. This isolation of total RNA could lead to the development of research tools to revolutionize the fields of stem cell biology and regenerative medicine research.<p><img src=\"https://s3.us-east-1.amazonaws.com/static.tto.c8e.ai/upitt/attachments/01545/0EMVv00000COkR1.png\"></p></img>Nitro oleic acid reduces blood glucose levels in diabetic mice, demonstrating comparable or superior efficacy to rosiglitazone.</p><p><h2>Description</h2>Hydractinia is a small colonial invertebrate, traditionally found growing on snail shells inhabited by hermit crabs. It has an extraordinary ability to regenerate its entire body throughout its lifetime. As a result, it is emerging as a model system in biomedical research. The extraction of total RNA now provides an opportunity to build a yeast two-hybrid library to perform yeast two-hybrid screens and identify and study novel protein-protein interactions.</p><p><h2>Applications</h2>•\tTreatment of type 2 diabetes \r<br>•\tManagement of insulin resistance \r<br>•\tPotential treatment for metabolic syndrome \r<br>•\tPPAR-γ modulation without traditional side effects \r<br>•\tRegulation of glucose metabolism</p><p><h2>Advantages</h2>•\tReduces blood glucose without causing weight gain \r<br>•\tSuperior insulin sensitization compared to existing treatments \r<br>•\tAvoids fluid retention side effects \r<br>•\tDifferent PPAR-γ binding mechanism than current drugs \r<br>•\tExtended activity through active metabolites</p><p><h2>Invention Readiness</h2>in vivo study has been completed using a murine model of diabetes (ob/ob -/- mice). The results showed that NO2-FA administration exerts anti-diabetic effects without the side effects commonly associated with thiazolidinediones (TZDs), such as peripheral edema, weight gain, and increased risk of cardiac failure.</p><p><h2>IP Status</h2><a target=\"_blank\" href=\"https://patents.google.com/patent/US10869850B2\">https://patents.google.com/patent/US10869850B2</a></p><p><h2>Related Publication(s)</h2><p>Li, Y., Zhang, J., Schopfer, F. J., Martynowski, D., Garcia-Barrio, M. T., Kovach, A., Suino-Powell, K., Baker, P. R. S., Freeman, B. A., Chen, Y. E., &amp; Xu, H. E. (2008). Molecular recognition of nitrated fatty acids by PPARγ. Nature Structural &amp;amp; Molecular Biology, 15(8), 865–867. <a target=\"_blank\" href=\"https://doi.org/10.1038/nsmb.1447\">https://doi.org/10.1038/nsmb.1447</a></p></p>","tags":[],"file_number":"01545","collections":[{"key":517,"name":"Cardiometabolic"}],"meta_description":"Nitrated fatty acids activate PPAR-γ to improve type 2 diabetes in mice, offering safer insulin sensitization.","image_url":"https://s3.us-east-1.amazonaws.com/static.tto.c8e.ai/upitt/attachments/01545/0EMVv00000COkR1.png","apriori_judge_output":"{\"scores\":{\"novelty\":3.0,\"potential_impact\":3.0,\"readiness\":3.0,\"scalability\":2.0,\"timeliness\":2.0},\"weighted_score\":2.9,\"risks\":[\"Outdated primary data (2007) implies lower timeliness\",\"Model organism (Hydractinia) may limit translational relevance\",\"Safety/clinical validation gaps for NO2-FA\",\"Potential regulatory hurdles for small molecules with PPAR-γ modulation\"],\"one_sentence_take\":\" Moderate novelty with translational promise hampered by age, limited readiness for clinical translation, and translational uncertainties from non-mammalian model.\"}","lead_inventor_name":"Bruce Freeman","lead_inventor_dept":"Med-Pharmacology and Chemical Biology","technology_type":"Therapeutic Modality","technology_subtype":"Small Molecule","therapeutic_areas":["Cardiovascular","Endocrinology and Metabolic Diseases"],"therapeutic_indications":["Diabetes"],"custom_tags":[],"all_tech_innovators":["Bruce A. Freeman"],"date_submitted":"2007-08-01"},"highlight":{},"matched_queries":null,"score":0.0}